更新于：2024-11-21

Allylestrenol

烯丙雌醇

更新于：2024-11-21

概要

概要

基本信息

药物类型

小分子化药

别名

17α-allylestr-4-en-17β-ol、3-deketo-17α-allyl-19-nortestosterone、Allyl estrenol

+ [4]

靶点

作用机制

PR激动剂(孕激素受体激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症

早产

非在研适应症-

原研机构

Chemical Works of Gedeon Richter Plc

在研机构

Chemical Works of Gedeon Richter Plc

非在研机构-

最高研发阶段批准上市

首次获批日期

中国 (2002-06-03),

早产

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C21H32O

InChIKeyATXHVCQZZJYMCF-XUDSTZEESA-N

CAS号432-60-0

关联

项与烯丙雌醇相关的临床试验

ChiCTR2100053693 / Suspended临床4期IIT

Randomized Controlled Trial of Allylestrenol Tablets in the Prevention of Late Abortion / Preterm Birth

开始日期2021-12-05

申办/合作机构-

CTR20140222 / Completed

烯丙雌醇片在健康女性受试者中的单次剂量、随机、开放生物等效性研究

研究健康女性受试者在空腹状态或进食高脂食物后，单次口服由河北创健药业有限公司生产的烯丙雌醇片和常州四药制药有限公司生产的烯丙雌醇片的相对生物利用度，评价两制剂间的生物等效性。

开始日期2014-12-06

申办/合作机构

乐声药业石家庄有限公司

100 项与烯丙雌醇相关的临床结果

登录后查看更多信息

100 项与烯丙雌醇相关的转化医学

登录后查看更多信息

100 项与烯丙雌醇相关的专利（医药）

登录后查看更多信息

129

项与烯丙雌醇相关的文献（医药）

2023-05-01·BJOG: An International Journal of Obstetrics & Gynaecology

Analysis of a maternal health medicines pipeline database 2000–2021: New candidates for the prevention and treatment of fetal growth restriction

Article

作者: Gülmezoglu, A. Metin ; Tong, Stephen ; Goldstein, Maya ; Ricci, Christina ; Lim, Shao ; Hastie, Roxanne ; Rushwan, Sara ; Ammerdorffer, Anne ; Vogel, Joshua P. ; Tuttle, Andrew ; McDougall, Annie R. A.

AbstractObjectiveThe Accelerating Innovation for Mothers project established a new database of candidate medicines under development between 2000 and 2021 for five pregnancy‐related conditions, including fetal growth restriction. The objective was to assess medicines for fetal growth restriction and their potential for clinical use globally.DesignLandscape analysis.SettingGlobal (focus on low‐ and middle‐income countries, LMICs).SampleDrugs, dietary supplements and biologics under investigation for prevention or treatment of fetal growth restriction.MethodsA research pipeline database of medicines was created through searching AdisInsight, PubMed and various grant and clinical trial databases. Analysis of clinical and preclinical candidates were descriptive.Main Outcomes MeasuresFetal growth restriction candidates in clinical development were identified and ranked as high, medium or low potential based on prespecified criteria, including efficacy, safety and accessibility.ResultsOf the 444 unique candidates in the database across all five pregnancy‐related conditions, 63 were for fetal growth restriction. Of these, 31 were in clinical development (phases I, II or III) and 32 were in preclinical development. Three candidates, aspirin, l‐arginine and vitamin D, were ranked as having high potential as preventive agents. There were no high‐potential candidates for treating fetal growth restriction, although five candidates were ranked as having medium potential: allylestrenol, dalteparin, omega‐3 fatty acids, tadalafil, and United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP).Conclusionsl‐Arginine, aspirin and vitamin D are promising, high‐potential preventative agents for fetal growth restriction. Based on the medicines pipeline, new pharmacological agents for fetal growth restriction are unlikely to emerge in the near future.

2022-02-01·Journal of Clinical Pharmacy and Therapeutics4区 · 医学

Real‐world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: A cross‐sectional analysis

4区 · 医学

Article

作者: Pang, Yan‐Yu ; Ma, Chun‐Lai

WHAT IS KNOWN AND OBJECTIVEApproximately half of the patients with threatened miscarriage suffer an abortion, and consistent medication therapy to prevent threatened miscarriage is lacking. Our goal was to investigate the real-world pharmacological treatment patterns of patients with threatened miscarriage in China, with a focus on the trend and rationality of progestogen use over the last 7 years.METHODSWe performed a cross-sectional analysis of data from the Hospital Prescription Analysis Cooperation Project that is overseen by the Chinese Pharmaceutical Association. Information was extracted from prescriptions of outpatients with threatened miscarriage between January 2014 and December 2020. We quantified the types of medications using the first level anatomical therapeutic chemical (ATC) classification code and the frequency of use of medicines classified as category X by the United States Food and Drug Administration (FDA). We also calculated the prevalence of the most frequently used progestogens by assessing prescription rates, determined the sum of the defined daily doses (DDDs) and defined daily cost (DDC) and evaluated the rationality of progestogens according to drug labels and guidelines.RESULTS AND DISCUSSIONOf the 91,464 patients included in this study, 69.4% were from the eastern region, 92.5% were from tertiary hospitals, and 72.9% were between 25 and 34 years old. The average number of medications per patient was 1.4. The following types of medicines were the most prevalent: "genitourinary system and sex hormones" (90.7%), "alimentary tract and metabolism" (10.8%) and "blood and blood-forming organs" (9.9%). Progestogens were prescribed for 81,080 patients (88.6%), among which oral progesterone (39.7%) was the most commonly used, followed by oral dydrogesterone (34.4%), progesterone injection (26.0%), oral allylestrenol (0.7%) and progesterone gel (0.4%). In other words, 10,991 (12.0%) patients used more than one progestogen, and the top three combinations were oral dydrogesterone plus progesterone injection (5.6%), oral progesterone plus progesterone injection (4.7%) and oral dydrogesterone plus oral progesterone (1.1%). The prescription rate of dydrogesterone increased gradually, whereas that of progesterone, especially progesterone injection, obviously decreased. Among 34,760 prescriptions of progestogens with complete usage information, the primary errors of progestogen use were "low frequency" (18.4%), "high single dose" (15.9%) and "low single dose" (11.3%). In addition, 137 prescriptions were identified with drug-progestogen interactions, and 61 were identified with contraindications for progestogens. A total of 4.5% of prescriptions included FDA category X medicines.WHAT IS NEW AND CONCLUSIONOur findings are the first to provide information on medication use in patients with threatened miscarriage over the last seven years in China. Medicines targeting the "genitourinary system and sex hormones," especially progestogens, were the most commonly prescribed medications, among which dydrogesterone was the most prevalent. However, it is remarkable that the use of progestogens for the treatment of threatened abortion is still controversial; thus, high-quality large sample studies are still required, especially among Chinese patients. Since usage errors in progestogen records and exposure to category X medicines were common, more efforts are needed to guarantee the safety and rationality of medicines used in pregnant women.

2011-07-01·Magnetic Resonance in Chemistry3区 · 化学

Using indirect covariance processing for structure elucidation of small molecules in cases of spectral crowding

3区 · 化学

Article

作者: Martin Jaeger ; Maarten Honing ; Pepijn E. T. J. Geutjes ; Ruud L. E. G. Aspers

AbstractIndirect and unsymmetrical indirect covariance NMR provide powerful tools to compute and visualize correlation information by transforming component spectra into combined spectral data matrices. Sensitive component spectra such as TOCSY, HSQC and NOESY can be quickly converted into experimentally insensitive or time‐consuming correlation spectra such as HSQC‐NOESY. The comparison of illustrative series of spectra from four steroids, dexamethasone, testosterone, allylestrenol and tibolone, renders the effects of resonance overlap on the ease of interpretation visible. The compounds are selected such that signal overlap increases systematically in the proton and carbon domain. Spectra are defined as light, moderate and heavy signal overlap, based on signal density. The investigation suggests that moderate spectral congestion in either proton or carbon domain leads to a number of artifacts that does not hamper signal assignment but lowers the level of confidence on de novo structure elucidation. Since the number of correlations usually increases through covariance processing, component spectra with severe spectral congestion in both dimensions are not suitable for covariance processing and the resulting spectra do not support structure confirmation or structure elucidation. The calculated spectra are compared with the corresponding experimental spectra with respect to their application in structure elucidation laboratory environments. Copyright © 2011 John Wiley & Sons, Ltd.

100 项与烯丙雌醇相关的药物交易

登录后查看更多信息